Abstract
Neutropenia induced by chemotherapy (CT) is an infection risk factor associated to greater morbidity/mortality and dose-limiting toxicity that on many occasions requires a reduction of the dose of cytostatics or a delay in the administration of treatment. This may have a negative effect on the patient's quality of life and even diminish the efficacy of the treatment, especially when the intention is to cure or prolong survival. Management of treatment or prophylaxis of grade 3–4 neutropenia and febrile neutropenia with myeloid growth factors (CSF) varies very much in clinical practice, both in the time of starting treatment and the types of patients it is given to. The need to generalise and facilitate practice based on clinical evidence has led the Spanish Society of Medical Oncology (SEOM) to prepare clinical practice guidelines on the use of myeloid growth factors.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Timmer-Bonte JN, de Boo TM, Smit HJ et al (2005) Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study. J Clin Oncol 23:7974–7984
Vogel CL, Wojtukiewicz MZ, Carroll RR et al (2005) First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 23:1178–1184
Bui BN, Chevallier B, Chevreau C et al (1995) Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity. J Clin Oncol 13:2629–2636
Doorduijn JK, van der Holt B, van Imhoff GW et al (2003) CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. J Clin Oncol 21:3041–3050
Citron ML, Berry DA, Cirrincione C et al (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431–1439
Chirivella I, Bermejo B, Insa A et al (2009) Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients. Breast Cancer Res Treat 114:479–484
Pfreundschuh M, Trumper L, Kloess M et al (2004) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 104:634–641
Radosavljevic D, Golubicic I, Gavrilovic D et al (2009) Do the time to chemotherapy response and the dose intensity have an impact on patient outcome in advanced non-small cell lung cancer? J BUON 14:203–209
Sarosy GA, Hussain MM, Seiden MV et al (2010) Ten-year follow-up of a phase 2 study of doseintense paclitaxel with cisplatin and cyclophosphamide as initial therapy for poor-prognosis, advanced-stage epithelial ovarian cancer. Cancer 116:1476–1484
Lyman GH, Kuderer NM (2004) The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia. Crit Rev Oncol Hematol 50:129–146
Cosler LE, Eldar-Lissai A, Culakova E et al (2007) Therapeutic use of granulocyte colonystimulating factors for established febrile neutropenia: effect on costs from a hospital perspective. Pharmacoeconomics 25:343–351
Bohlius J, Herbst C, Reiser M et al (2008) Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database Syst Rev (4):CD003189
Sung L, Nathan PC, Alibhai SM et al (2007) Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection. Ann Intern Med 147:400–411
Kuderer NM, Dale DC, Crawford J, Lyman GH (2007) Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 25:3158–3167
Dale DC, McCarter GC, Crawford J, Lyman GH (2003) Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials. J Natl Compr Canc Netw 1:440–454
Clark OA, Lyman GH, Castro AA et al (2005) Colony-stimulating factors for chemotherapyinduced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol 23:4198–4214
Berghmans T, Paesmans M, Lafitte JJ et al (2002) Therapeutic use of granulocyte and granulocytemacrophage colony-stimulating factors in febrile neutropenic cancer patients. A systematic review of the literature with meta-analysis. Support Care Cancer 10:181–188
Garcia-Carbonero R, Mayordomo JI, Tornamira MV et al (2001) Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. J Natl Cancer Inst 93:31–38
Saven A, Schwartzberg L, Kaywin P et al (2006) Randomized, double-blind, phase 2 study evaluating same-day vs next-day administration of pegfilgrastim with R-CHOP in non-Hodgkin's lymphoma patients. J Clin Oncol (Meeting Abstract) 24:7570
Yardley DA, Burris HA III, Farley CP et al (2008) A phase II feasibility trial of dose-dense docetaxel followed by doxorubicin/cyclophosphamide as adjuvant or neoadjuvant treatment for women with node-positive or high-risk node-negative breast cancer. Clin Breast Cancer 8:242–248
Petros WP, Crawford J (1997) Safety of concomitant use of granulocyte-macrophage colony-stimulating factor or granulocyte-macrophage colonystimulating factor with cytotoxic chemotherapy agents. Curr Opin Hematol 4:213–216
Bunn PJ, Crowley J, Kelly K et al (1995) Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of Southwest Oncology Group. J Clin Oncol 13:1632–1641. Erratum in: J Clin Oncol 1995;13:2860
Momin F, Kraut M, Lattin P, Valdivieso M (1992) Thrombocytopenia in patients receiving chemoradiotherapy and G-CSF for locally advanced nonsmall cell lung cancer. Proc Annu Meet Am Soc Clin Oncol 11:983a
Morstyn G, Campbell L, Lieschke G et al (1989) Treatment of chemotherapy-induced neutropenia by subcutaneously administered granulocyte colony-stimulating factor with optimization of dose and duration of therapy. J Clin Oncol 7:1554–1562
Ribas A, Albanell J, Bellmunt J et al (1996) Fiveday course of granulocyte colony-stimulating factor in patients with prolonged neutropenia after adjuvant chemotherapy for breast cancer is a safe and cost-effective schedule to maintain doseintensity. J Clin Oncol 14:1573–1580
Almenar D, Mayans J, Juan OR et al (2009) Peg-filgrastrim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in spain. Results of the LEARN study. Eur J Cancer Care 18:280–286
Von Minckwitz G, Schwenkglenks M, Skacel T et al (2009) Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastrim primary prophylaxis versus current practice neutropenia management: results from an integrated analysis. Eur J Cancer 45:608–617
Marina J, Carabantes FJ, Escrivá de Romani S et al (2009) Current practice of prophylaxis with granulocyte colony-stimulating factors for preventing chemotherapy-induced neutropenia in breast cancer patients in Spain. Eur J Cancer 7[Suppl 1]:181 (abst P-3019)
Crawford J, Kreisman H, Garewal H et al (1997) The impact of Filgrastim schedule variation on hematopoietic recovery post-chemotherapy. Ann Oncol 8:1117–1124
Koumakis G, Vassilomanolakis M, Barbounis V et al (1999) Optimal timing (Preemptive versus supportive) of granulocyte colony-stimulating factor administration following high-dose cyclophosphamide. Oncology 56:28–35
Engert A, del Giglio A, Bias P et al (2009) Incidence of febrile neutropenia and myelotoxicity of chemotherapy: a meta-analysis of biosimilar G-CSF studies in breast cancer, lung cancer, and non-Hodgkin's lymphoma. Onkologie 32:599–604
Gascon P, Fuhr U, Sörgel F et al (2010) Development of a new G-CSF product based on biosimilarity assessment. Ann Oncol 21:1419–1429
Siena S, Piccart MJ, Holmes FA et al (2003) A combined analysis of two pivotal randomized trials of a single dose of Pegfilgrastrim per chemotherapy cycle and daily Filgrastrim in patients with stage II–IV breast cancer. Oncol Rep 10:715–724
Pinto L, Liu Z, Doan Q et al (2007) Comparison of pegfilgrastrim with filgrastrim on febrile neutropenia, grade IV neutropenia and bone pain: meta-analysis of randomized controlled trials. Curr Med Res Opin 23:2283–2295
Aapro MS, Bohlius J, Cameron DA et al (2011) 2011 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47:8–32
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Muñoz Langa, J., Gascón, P. & de Castro, J. SEOM clinical guidelines for myeloid growth factors. Clin Transl Oncol 14, 491–498 (2012). https://doi.org/10.1007/s12094-012-0830-2
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s12094-012-0830-2